1. Scrip
  2. >>Business

Start-Up Quarterly Statistics, Q2 2016

 
• By Deanna Kamienski

A review of biopharma start-up dealmaking and financing from April through June 2016, based on data from Strategic Transactions.

trading

In the second quarter, start-up biopharmas raised $1.63bn, an increase over the $1.34bn raised in the first quarter of 2016, but well down from the impressive $2.47bn raised back in Q2 2015. New and emerging biopharma companies also penned 26 alliances and signed five acquisitions.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Can European Biotech Survive And Thrive In Era Of Instability?

 
• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies

 
• By Mandy Jackson

Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.